This approach can drive sustained reprogramming of the tumor microenvironment in both primary and metastatic sites. Our approach overcomes the central challenge of cancers’ resistance to current treatments and enables the development of a new paradigm for cancer cure in the future.

We have a rapidly expanding and advancing pipeline of novel monotherapy and combination product candidates that have shown a consistent safety profile and increasing evidence of efficacy surrogates such as biomarkers in studies to date.

Our Vision

We aim to lead the world in tumor re-engineering, delivering medicines of value to patients with cancer.

Our Strategy

PsiOxus is a clinical stage oncology company pioneering systemic immune oncology products that drives sustained reprogramming of the tumor microenvironment to overcome the central challenge of resistance to therapy.

Our Values

We choose to fight cancer

alongside all of those patients who did not choose to be in that fight.

We choose to make a difference

because innovation and science can push the boundaries of what is possible.

We choose to work with honesty and integrity

because we recognise the important responsibilities that we have.

We choose to respect each other and our partners

because by working together we can achieve so much more than by working alone.

John Beadle, CEO, PsiOxus Therapeutics - Video